亚太地区系统性红斑狼疮的流行病学、治疗与疾病负担:靶向文献综述
本文通过靶向文献综述,汇总亚太地区系统性红斑狼疮的流行病学、现行治疗与疾病负担证据,共纳入70项研究。结果显示发病率0.9–8.4/10万人年、患病率3.7–127/10万,亚洲患者疾病严重度、活动度及器官损害更高,治疗模式存在地区差异,疾病活动度升高与经济负担和不良生活质量相关。
要点
- 亚太地区SLE发病率0.9–8.4/10万人年,患病率3.7–127/10万,近期数据有限。
- 亚洲患者疾病严重度、活动度、器官损害及肾受累风险高于其他族裔。
- 常用治疗包括贝利尤单抗、羟氯喹、环磷酰胺、他克莫司、硫唑嘌呤、吗替麦考酚酯和糖皮质激素,处方模式地区差异大。
核心结论
- SLE在亚太地区仍存在显著未满足的医疗需求,需要耐受性好且有效的新型治疗。
- 需进一步证据以更好刻画疾病特征并全面评估亚太地区SLE的负担与影响。
研究设计与样本
- 靶向文献综述,检索Medline数据库(2008—2018年)、会议论文集及其他补充来源。
- 共纳入70项研究,分别来自中国15项、日本13项、台湾12项、韩国9项、澳大利亚7项、香港6项、新加坡4项及亚太多地4项。
主要发现
- 发病率范围为0.9–8.4/10万人年,患病率范围为3.7–127/10万,但近期数据有限。
- 亚洲SLE患者疾病严重度更高、SLE疾病活动指数评分更高、器官损害累积更多,发病率和死亡率升高,且更易出现肾脏受累。
- 亚洲人群发生SLE的风险更高。
- 疾病活动度升高与亚太地区SLE患者的高经济负担和差生活质量相关。
关键数值与推荐
- 常规使用的SLE治疗包括贝利尤单抗、羟氯喹、环磷酰胺、他克莫司、硫唑嘌呤、吗替麦考酚酯和糖皮质激素。
- 处方模式在亚太各地区之间存在差异。
临床怎么用
- 临床应关注亚太地区亚洲SLE患者更高的疾病活动度、器官损害和肾受累风险,加强监测与干预。
- 治疗选择需结合区域处方差异与可及性,并重视疾病活动度对经济负担和生活质量的影响。
局限性
- 近期流行病学数据有限,亚太部分地区数据匮乏,难以全面刻画疾病负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To understand the epidemiology, current treatment, and disease burden of systemic lupus erythematosus (SLE) in the Asia Pacific (APAC) region. METHODS: A targeted literature review of published evidence on SLE in the APAC region was conducted, using the Medline database (2008-2018), conference proceedings, and other supplementary sources. RESULTS: The current review identified 70 studies conducted in China (n = 15), Japan (n = 13), Taiwan (n = 12), Korea (n = 9), Australia (n = 7), Hong Kong (n = 6), Singapore (n = 4), and multiple places within the APAC region (n = 4). Incidence rates (per 100,000 persons per year) ranged from 0.9-8.4, while prevalence rates ranged from 3.7-127 (per 100,000 persons); however, recent data were limited. Asian patients with SLE were reported to have higher disease severity, disease activity (higher SLE disease activity index scores), and organ damage accrual, along with increased morbidity, mortality, and susceptibility to renal involvement compared with other ethnicities in the APAC region. The risk of developing SLE is higher in the Asian population. Routinely used SLE therapies included belimumab, hydroxychloroquine, cyclophosphamide, tacrolimus, azathioprine, mycophenolate mofetil, and glucocorticoids; however, prescribing patterns varied across the region. Increased disease activity was associated with high economic burden and poor quality of life for SLE patients in the APAC region. CONCLUSION: SLE remains a disease with a significant unmet medical need for an innovative therapy that is well-tolerated and effective for patients in the APAC region. Further evidence is required to better characterize the disease and fully capture the burden and impact of SLE in the APAC region. This review has highlighted where there is a paucity of data from patients across the APAC region.
引用
- Tanaka Y, O'Neill S, Li M, et al. Systemic Lupus Erythematosus: Targeted Literature Review of the Epidemiology, Current Treatment, and Disease Burden in the Asia Pacific Region. Arthritis Care Res (Hoboken). 2022. PMID: 32841537. doi:10.1002/acr.24431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。